Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Financing from Swiss investors begins long-term nanoparticle drug development programme

Abstract:
Midatech Group, a world leader in nanotechnology, today announces the formation of a Basel-based Swiss drug development subsidiary, PharMida AG. Formation of this subsidiary follows an investment by a group of Switzerland-based private investors into Midatech Ltd. The mandate of PharMida is to develop a strong portfolio of clinically validated gold nanoparticle-drug combinations. Furthermore, PharMida will have the responsibility to project manage in-house drug development, commercial partnerships, and out-licensing opportunities in order to leverage the rich collection of the already existing and most promising Midatech Ltd products or product lines in Life Sciences. PharMida will be headed by Professor Fritz R. Buhler as Chairman, and Dr Jan Mous as CEO.

Financing from Swiss investors begins long-term nanoparticle drug development programme

Oxford, UK | Posted on November 17th, 2008

Professor Fritz Buhler, Chairman of PharMida, is Professor of Pharmaceutical Medicine and Pathophysiology as well as of Internal Medicine and Cardiology at the Faculty of Medicine, Universities of Basel. He has a wealth of experience in pharmaceutical development having held a number of senior positions in academia and industry, including Head of Worldwide Clinical R&D at F. Hoffman-La Roche, Director of the European Centre of Pharmaceutical Medicine and co-Founder of International Biomedicine Management Partners, Basel, and Health Innoventures, New York.

Dr Jan Mous, PharMidaís new CEO, has a strong background in research and development, and many yearsí experience at senior level in a number of biotech companies. Most recently Dr Mous was President and CEO of IntegraGen, and prior to that he held the position of CSO and was member of the Executive Board of LION bioscience. From 1985 to 2000, Dr Mous enjoyed a successful career at F. Hoffmann-La Roche in Basel.

Professor Thomas Rademacher, Founder and Chairman of Midatech Group, commented: "This is an extremely important step in the development of Midatech and its nanoparticle technology. It is a great privilege to be partnering with such a high calibre team, who between them bring an unrivalled level of expertise and experience in the pharmaceutical sector. I am looking forward to working with Professor Buhler and Dr Mous to develop Midatechís innovative nanoparticle technology to its full potential."

"I am delighted to be joining PharMida at its inception, and look forward with great anticipation to being a part of the journey that will see this subsidiary develop the potential of its exciting technology," commented Jan Mous, CEO.

"The nanoparticle technology to be developed by PharMida is very promising and I have no doubt will prove to be of great importance to the development better therapeutic applications for patients in need," added Professor Fritz R. Buhler, Chairman.



####

About Midatech Group
Midatech Group Ltd, UK, is a world leader in the design, synthesis and manufacture of biocompatible nanoparticles. These nanoparticles can be used to create a wide variety of products with novel characteristics, functions and applications for a number of industry segments including life sciences, electronics and fine chemicals.

Founded in 2000, Midatech Ltd is a private company headquartered in Abingdon, Oxford, UK. In 2005 it registered its manufacturing facility ñ Midatech Biogune S.L. ñ in Bilbao, Spain, which became fully operational for cGMP standard design and manufacturing of API nanoparticles In March 2007. In 2008 Midatech Ltd further expanded with the opening of PharMida AG in Basel, Switzerland, which is responsible for developing Midatech's technology in the life sciences arena.

The Technology in life sciences - a paradigm shift in drug development and drug delivery

Midatechís biocompatible nanoparticles possess a number of unique properties that make them ideal for diagnostic and therapeutic applications.

The nanoparticles are water soluble and can be designed to either diffuse freely in vivo, or to target specific cells. With a diameter of less than 5nm, unbound nanoparticles are freely excreted from the kidneys, reducing the likelihood of non-specific in vivo accumulation. Their size enables drug delivery via different routes of administration, such as parental or intranasal. Their stability to enzymatic digestion may also permit oral therapy. Nanoparticles can be designed to be invisible to the host immune system with multiple ligands attached to a single nanoparticle allowing multivalent drug or multi-drug delivery on a single particle. In addition, as the nanoparticles self-assemble in a single step chemical process manufacturing is simple, safe, scaleable and low cost.

Midatech Ltd. has exclusive world-wide IP for the technology covering design, manufacture and application/use of nanoparticles in both diagnostic and therapeutic pharmaceutical areas as well as in other industries. It also has exclusive world-wide rights for technology relating to the synthesis and applications of self-assembling nanoparticles.

For more information, please click here

Contacts:
Kathryn Robertson

+44 (0)1260 296 506

Copyright © Midatech Group

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

New Hopes for Treatment of Intestine Cancer by Edible Nanodrug March 2nd, 2015

Imec, Holst Centre and Renesas Present World’s Lowest Power 2.4GHz Radio Chip for Bluetooth Low Energy March 1st, 2015

Imec, Murata, and Huawei Introduce Breakthrough Solution for TX-to-RX Isolation in Reconfigurable, Multiband Front-End Modules for Mobile Phones: Electrical-Balance Duplexers Pave the Way to Integrated Solution for TX-to-RX Isolation March 1st, 2015

Imec Demonstrates Compact Wavelength-Division Multiplexing CMOS Silicon Photonics Transceiver March 1st, 2015

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Silicon Catalyst Announces Partnership With imec to Support Semiconductor Start-Ups February 23rd, 2015

Ligar secures investment from Wallace Corporation to commercialise polymers that pick out good and bad molecules: Ground-breaking science innovation removes molecules in the wrong place from liquids February 15th, 2015

Harris & Harris Group Portfolio Company D-Wave Systems Raises an Additional $29 Million (CAD), Closing 2014 Financing at $62 Million (CAD) February 2nd, 2015

Ref signals deep impact as EPSRC announces £30 million for impact acceleration accounts (IAA) January 21st, 2015

Nanomedicine

New Hopes for Treatment of Intestine Cancer by Edible Nanodrug March 2nd, 2015

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

Novel Method to Determine Optical Purity of Drug Components March 1st, 2015

Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015

Announcements

New Hopes for Treatment of Intestine Cancer by Edible Nanodrug March 2nd, 2015

Imec Demonstrates Compact Wavelength-Division Multiplexing CMOS Silicon Photonics Transceiver March 1st, 2015

onic Present breakthrough in CMOS-based Transceivers for mm-Wave Radar Systems March 1st, 2015

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE